UNIGE document Scientific Article
previous document  unige:45738  next document
add to browser collection

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer

Van den Brande, J
Schöffski, P
Schellens, J H M
Duffaud, F
Weigang-Köhler, K
Reinke, F
Wanders, J
show hidden authors show all authors [1 - 11]
Published in British journal of cancer. 2003, vol. 88, no. 5, p. 648-53
Abstract Cancer of the colon and rectum is one of the most frequent malignancies both in the US and Europe. Standard palliative therapy is based on 5-fluorouracil/folinic acid combinations, with or without oxaliplatin or irinotecan, given intravenously. Oral medication has the advantage of greater patient convenience and acceptance and potential cost savings. S-1 is a new oral fluorinated pyrimidine derivative. In a nonrandomized phase II study, patients with advanced/metastatic colorectal cancer were treated with S-1 at 40 mg m-2 b.i.d. for 28 consecutive days, repeated every 5 weeks, but by amendment the dose was reduced to 35 mg m-2 during the study because of a higher than expected number of severe adverse drug reactions. In total 47 patients with colorectal cancer were included. In the 37 evaluable patients there were nine partial responses (24%), 17 stable diseases (46%) and 11 patients had progressive disease (30%). Diarrhoea occurred frequently and was often severe: in the 40 and 35 mg m-2 group, respectively, 38 and 35% of the patients experienced grade 3-4 diarrhoea. The other toxicities were limited and manageable. S-1 is active in advanced colorectal cancer, but in order to establish a safer dose the drug should be subject to further investigations.
Keywords AgedAntimetabolites, Antineoplastic/adverse effects/therapeutic useColorectal Neoplasms/drug therapy/pathologyDrug CombinationsFemaleHumansMaleMiddle AgedNeoplasm MetastasisOxonic Acid/adverse effects/therapeutic usePyridines/adverse effects/therapeutic useTegafur/adverse effects/therapeutic useTreatment Outcome
PMID: 12659110
Full text
Article (Published version) (117 Kb) - public document Free access
Research group Groupe Roth Arnaud (oncologie) (285)
(ISO format)
VAN DEN BRANDE, J et al. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. In: British journal of cancer, 2003, vol. 88, n° 5, p. 648-53. doi: 10.1038/sj.bjc.6600781 https://archive-ouverte.unige.ch/unige:45738

462 hits



Deposited on : 2015-01-22

Export document
Format :
Citation style :